Anticoagulant Factor Concentrates in Disseminated Intravascular Coagulation: Rationale for Use and Clinical Experience

 

 Buy Article Permissions and Reprints

ABSTRACT

Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also attenuate inflammatory responses during sepsis. Low circulating levels of AT and protein C have been associated with poor outcome. Replacement therapy with AT, activated protein C (APC), and TFPI has been shown to attenuate thrombin generation and to reduce mortality in experimental sepsis models. Experience with AT and APC in patients is promising. Data from large phase III trials of AT and APC as treatment of patients with severe sepsis will soon be available. Recombinant TFPI is currently in phase II clinical trials for severe sepsis.

REFERENCES

• 1 Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.  Chest . 1992;  101 816-823
  CrossrefPubMedGoogle Scholar
• 2 de Jonge E, Levi M, Stoutenbeek C P, van Deventer J S. Current drug treatment strategies for disseminated intravascular coagulation.  Drugs . 1998;  55 767 Review-777 Review
  PubMedGoogle Scholar
• 3 Levi M, ten Cate H. Disseminated intravascular coagulation.  N Engl J Med . 1999;  341 586-592
  CrossrefPubMedGoogle Scholar
• 4 Ryan J, Brett J, Tijburg P. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface.  Blood . 1992;  80 966-974
  PubMedGoogle Scholar
• 5 Key N S, Slungaard A, Dandelet L. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.  Blood . 1998;  91 4216-4223
  PubMedGoogle Scholar
• 6 Wilcox J N, Smith K M, Schwartz S M, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.  Proc Natl Acad Sci USA . 1989;  86 2839-2843
  PubMedGoogle Scholar
• 7 Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.  Thromb Haemost . 1983;  49 5-7
  PubMedGoogle Scholar
• 8 Rivers R P, Hathaway W E, Weston W L. The endotoxin-induced coagulant activity of human monocytes.  Br J Haematol . 1975;  30 311-316
  CrossrefPubMedGoogle Scholar
• 9 Moldow C F, Bach R R, Staskus K, Rick P D. Induction of endothelial tissue factor by endotoxin and its precursors.  Thromb Haemost . 1993;  70 702-706
  PubMedGoogle Scholar
• 10 Francis J L, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy.  Semin Thromb Hemost . 1998;  24 93-109
  PubMedGoogle Scholar
• 11 Lawson C A, Yan S D, Yan S F. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation.  J Clin Invest . 1997;  99 1729-1738
  PubMedGoogle Scholar
• 12 Bach R R, Moldow C F. Mechanism of tissue factor activation on HL-60 cells.  Blood . 1997;  89 3270-3276
  PubMedGoogle Scholar
• 13 Levi M, ten Cate H, Bauer K A. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.  J Clin Invest . 1994;  93 114-120
  CrossrefPubMedGoogle Scholar
• 14 Nuijens J H, Huijbregts C C, Eerenberg-Belmer A J. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.  Blood . 1988;  72 1841-1848
  PubMedGoogle Scholar
• 15 Taylor F BJ, Chang A, Ruf W. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.  Circulatory Shock . 1991;  33 127-134
  PubMedGoogle Scholar
• 16 Taylor F B, Chang A C, Peer G. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli Blood .  1998;  91 1609-1615
  PubMedGoogle Scholar
• 17 Creasey A A, Chang A C, Feigen L. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest . 1993;  91 2850-2856
  CrossrefPubMedGoogle Scholar
• 18 Rao L V, Nordfang O, Hoang A D, Pendurthi U R. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity.  Blood . 1995;  85 121-129
  PubMedGoogle Scholar
• 19 Mammen E F. Antithrombin: Its physiological importance and role in DIC.  Semin Thromb Hemost . 1998;  24 19-25
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Opal S M, Thijs L G. New potential therapeutic modalities: Antithrombin III.  Sepsis . 1999;  3 153-159
  CrossrefPubMedGoogle Scholar
• 21 Mammen E F. Clinical relevance of antithrombin deficiencies.  Semin Hematol . 1995;  32 2-6
  PubMedGoogle Scholar
• 22 Büller H R, ten Cate W J. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.  Am J Med . 1989;  87 44S Review-48S Review
  PubMedGoogle Scholar
• 23 Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution.  Eur J Haematol . 1989;  43 22-28
  PubMedGoogle Scholar
• 24 Mann L TJ, Jensenius J C, Simonsen M, Abildgaard U. Antithrombin 3.  Protection against death after injection of thromboplastin. Science . 1969;  166 517-518
  PubMedGoogle Scholar
• 25 Taylor F BJ, Emerson T EJ, Jordan R, Chang A K, Blick, K E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.  Circulatory Shock . 1988;  26 227-235
  PubMedGoogle Scholar
• 26 Minnema M C, Chang A C, Jansen P M. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood .  2000;  95 1117-1123
  PubMedGoogle Scholar
• 27 Kessler C M, Tang Z, Jacobs H M, Szymanski L M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity.  Blood . 1997;  89 4393-4401
  PubMedGoogle Scholar
• 28 Dickneite G. Antithrombin III in animal models of sepsis and organ failure.  Semin Thromb Hemost . 1998;  24 61-69
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin.  Crit Care Med . 1999;  27 597-604
  PubMedGoogle Scholar
• 30 Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study.  Thromb Res . 1985;  39 81-89
  CrossrefPubMedGoogle Scholar
• 31 Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation.  Semin Thromb Hemost . 1989;  15 347-352
  PubMedGoogle Scholar
• 32 Fourrier F, Chopin C, Huart J J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.  Chest . 1993;  104 882-888
  PubMedGoogle Scholar
• 33 Baudo F, Caimi T M, de Cataldo F. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study.  Intensive Care Med . 1998;  24 336-342
  CrossrefPubMedGoogle Scholar
• 34 Eisele B, Lamy M, Thijs L G. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.  Intensive Care Med . 1998;  24 663-672
  CrossrefPubMedGoogle Scholar
• 35 Inthorn D, Hoffmann J N, Hartl W H, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.  Shock . 1998;  10 90-96
  PubMedGoogle Scholar
• 36 Inthorn D, Hoffmann J N, Hartl W H, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction.  Shock . 1997;  8 328-334
  PubMedGoogle Scholar
• 37 Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation.  Thromb Haemost . 1999;  82 695-705
  PubMedGoogle Scholar
• 38 Maki M, Terao T, Ikenoue T. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial.  Gynecol Obstet Invest . 1987;  23 230-240
  PubMedGoogle Scholar
• 39 Ilias W, List W, Decruyenaere J. Antithrombin III in patients with severe sepsis: A pharmacokinetic study.  Intensive Care Med . 2000;  26 704-715
  CrossrefPubMedGoogle Scholar
• 40 Riess H. Antithrombin in severe sepsis-``new'' indication of an ``old'' drug?.  Intensive Care Med . 2000;  26 657 (Editorial)-659 (Editorial)
  PubMedGoogle Scholar
• 41 Dreyfus M, Magny J F, Bridey F. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.  N Engl J Med . 1991;  325 1565-1568
  CrossrefPubMedGoogle Scholar
• 42 Esmon C T, Xu J, Gu J M. Endothelial protein C receptor.  Thromb Haemost . 1999;  82 251-258
  PubMedGoogle Scholar
• 43 Fijnvandraat K, Derkx B, Peters M. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality.  Thromb Haemost . 1995;  73 15-20
  PubMedGoogle Scholar
• 44 Taylor Jr B F. Protein S, C4b binding protein, and the hypercoagulable state.  J Lab Clin Med . 1992;  119 596 Editorial and comment-597 Editorial and comment
  PubMedGoogle Scholar
• 45 Nawroth P P, Handley D A, Esmon C T, Stern D M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.  Proc Natl Acad Sci USA . 1986;  83 3460-3464
  PubMedGoogle Scholar
• 46 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med . 1986;  163 740-745
  CrossrefPubMedGoogle Scholar
• 47 Fukudome K, Esmon C T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor.  J Biol Chem . 1994;  269 26486-26491
  PubMedGoogle Scholar
• 48 Boehme M W, Deng Y, Raeth U. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies.  Immunology . 1996;  87 134-140
  PubMedGoogle Scholar
• 49 Slungaard A, Vercellotti G M, Tran T, Gleich G J, Key N S. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease.  J Clin Invest . 1993;  91 1721-1730
  PubMedGoogle Scholar
• 50 Hesselvik J F, Malm J, Dahlbäck B, Blombäck M. Protein C, protein S and C4b-binding protein in severe infection and septic shock.  Thromb Haemost . 1991;  65 126-129
  PubMedGoogle Scholar
• 51 Takahashi Y, Hosaka Y, Imada K. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin.  Thromb Haemost . 1997;  77 789-795
  PubMedGoogle Scholar
• 52 Uchiba M, Okajima K, Murakami K. Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats.  Am J Hematol . 1997;  54 118-123
  CrossrefPubMedGoogle Scholar
• 53 Mohri M, Gonda Y, Oka M. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis).  Blood Coagul Fibrinolysis . 1997;  8 274-283
  PubMedGoogle Scholar
• 54 Uchiba M, Okajima K, Murakami K. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation.  Am J Physiol . 1997;  273 L889-L894
  PubMedGoogle Scholar
• 55 Nakashima M, Uematsu T, Umemura K, Maruyama I, Tsuruta K. A novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers.  J Clin Pharmacol . 1998;  38 540-544
  PubMedGoogle Scholar
• 56 Nakashima M, Kanamaru M, Umemura K, Tsuruta K. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers.  J Clin Pharmacol . 1998;  38 40-44
  PubMedGoogle Scholar
• 57 Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation.  Thromb Haemost . 1999;  82 718-721
  PubMedGoogle Scholar
• 58 Taylor F BJ, Chang A, Esmon C T. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest . 1987;  79 918-925
  CrossrefPubMedGoogle Scholar
• 59 Ettingshausen C E, Veldmann A, Beeg T. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.  Semin Thromb Hemost . 1999;  25 537-541
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Rintala E, Kauppila M, Seppala O P. Protein C substitution in sepsis-associated purpura fulminans.  Crit Care Med . 2000;  28 2373-2378
  PubMedGoogle Scholar
• 61 Rivard G E, David M, Farrell C, Schwarz H P. Treatment of purpura fulminans in meningococcemia with protein C concentrate.  J Pediatr . 1995;  126 646-652
  PubMedGoogle Scholar
• 62 Smith O P, White B, Vaughan D. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans.  Lancet . 1997;  350 1590-1593
  CrossrefPubMedGoogle Scholar
• 63 Gerson W T, Dickerman J D, Bovill E G, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate.  Pediatrics . 1993;  91 418-422
  PubMedGoogle Scholar
• 64 Bernard G R, Hartman D L, Helterbrand J D, Fisher C J. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis.  Crit Care Med . 1998;  27 S4
  PubMedGoogle Scholar
• 65 Bernhard G R, Vincent J-L, Laterre P-F. Efficacy and safety of recombinanat human activated protein C for severe sepsis.  N Engl J Med . 2001;  344 699-709
  CrossrefPubMedGoogle Scholar
• 66 Taylor F, Chang A, Ferrell G. C4b-binding protein exacerbates the host response to Escherichia coli Blood .  1991;  78 357-363
  PubMedGoogle Scholar
• 67 Creasey A A. New potential therapeutic modalities: Tissue factor pathway inhibitor.  Sepsis . 1999;  3 173-182
  CrossrefPubMedGoogle Scholar
• 68 Carr C, Bild G S, Chang A C. Recombinant E. coli- derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock.  Circulatory Shock . 1994;  44 126-137
  PubMedGoogle Scholar
• 69 de Jonge E, Dekkers P E, Creasey A A. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.  Blood . 2000;  95 1124-1129
  PubMedGoogle Scholar
• 70 Girard T J, Warren L A, Novotny W F. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.  Nature . 1989;  338 518-520
  Google Scholar
• 71 Novotny W F, Girard T J, Miletich J P, Broze Jr J G. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.  J Biol Chem . 1989;  264 18832-18837
  Google Scholar
• 72 Novotny W F, Girard T J, Miletich J P, Broze Jr J G. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.  Blood . 1988;  72 2020-2025
  Google Scholar
• 73 Ameri A, Kuppuswamy M N, Basu S, Bajaj S P. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators.  Blood . 1992;  79 3219-3226
  PubMedGoogle Scholar
• 74 Lindahl A K. Tissue factor pathway inhibitor: From unknown coagulation inhibitor to major antithrombotic principle [see comments].  Cardiovascular Research . 1997;  33 286 Review-291 Review
  PubMedGoogle Scholar
• 75 Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor.  Thromb Res . 1995;  80 339-348
  CrossrefPubMedGoogle Scholar
• 76 Novotny W F, Brown S G, Miletich J P, Rader D J, Broze Jr J G. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.  Blood . 1991;  78 387-393
  PubMedGoogle Scholar
• 77 Sabharwal A K, Bajaj S P, Ameri A. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis [published erratum appears in Am J Respir Crit Care Med 1995;151:following 2118].  Am J Respir Crit Care Med . 1995;  151 758-767
  PubMedGoogle Scholar
• 78 Day K C, Hoffman L C, Palmier M O. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit.  Blood . 1990;  76 1538-1545
  PubMedGoogle Scholar
• 79 Bregengard C, Nordfang O, Wildgoose P. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.  Blood Coagul Fibrinolysis . 1993;  4 699-706
  PubMedGoogle Scholar
• 80 Randolph M M, White G L, Kosanke S D. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli-a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli Thromb Haemost .  1998;  79 1048-1053
  PubMedGoogle Scholar
• 81 Camerota A J, Creasey A A, Patla V, Larkin V A, Fink M P. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis.  J Infect Dis . 1998;  177 668-676
  CrossrefPubMedGoogle Scholar
• 82 Kemme M J, Burggraaf J, Schoemaker R C. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor.  Clin Pharmacol Ther . 2000;  67 504-511
  CrossrefPubMedGoogle Scholar
• 83 Esmon C T. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?.  Blood . 2000;  95 1113-1116
  PubMedGoogle Scholar
• 84 Coalson J J, Benjamin B, Archer L T. Prolonged shock in the baboon subjected to infusion of E. coli endotoxin.  Circulatory Shock . 1978;  5 423-437
  PubMedGoogle Scholar
• 85 Taylor F BJ, Chang A C, Peer G T. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.  Blood . 1991;  78 364-368
  PubMedGoogle Scholar
• 86 Cirino G, Cicala C, Bucci M. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo.  J Clin Invest . 1997;  99 2446-2451
  PubMedGoogle Scholar
• 87 Senden N H, Jeunhomme T M, Heemskerk J W. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells.  J Immunol . 1998;  161 4318-4324
  PubMedGoogle Scholar
• 88 Johnson K, Choi Y, DeGroot E. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.  J Immunol . 1998;  160 5130-5135
  PubMedGoogle Scholar
• 89 Jones A, Geczy C L. Thrombin and factor Xa enhance the production of interleukin-1.  Immunology . 1990;  71 236-241
  PubMedGoogle Scholar
• 90 Hoffman M, Cooper S T. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms.  Blood Cells Mol Dis . 1995;  21 156-167
  CrossrefPubMedGoogle Scholar
• 91 Kranzhofer R, Clinton S K, Ishii K. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.  Circ Res . 1996;  79 286-294
  PubMedGoogle Scholar
• 92 Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells.  Immunology . 1996;  88 76-81
  CrossrefPubMedGoogle Scholar
• 93 Grandaliano G, Valente A J, Abboud H E. A novel biologic activity of thrombin: Stimulation of monocyte chemotactic protein production.  J Exp Med . 1994;  179 1737-1741
  CrossrefPubMedGoogle Scholar
• 94 Colotta F, Sciacca F L, Sironi M. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.  Am J Pathol . 1994;  144 975-985
  PubMedGoogle Scholar
• 95 Anrather D, Millan M T, Palmetshofer A. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF.  J Immunol . 1997;  159 5620-5628
  PubMedGoogle Scholar
• 96 Kahn M L, Nakanishi-Matsui M, Shapiro M J, Ishihara H, Coughlin S R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.  J Clin Invest . 1999;  103 879-887
  CrossrefPubMedGoogle Scholar
• 97 Camerer E, Huang W, Coughlin S R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.  Proc Natl Acad Sci USA . 2000;  97 5255-5260
  CrossrefPubMedGoogle Scholar
• 98 Grey S T, Tsuchida A, Hau H. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.  J Immunol . 1994;  153 3664-3672
  PubMedGoogle Scholar
• 99 Hancock W W, Grey S T, Hau L. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses.  Transplantation . 1995;  60 1525-1532
  CrossrefPubMedGoogle Scholar
• 100 Grinnell B W, Hermann R B, Yan S B. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide.  Glycobiology . 1994;  4 221-225
  PubMedGoogle Scholar
• 101 Taylor F BJ, Chang A, Hinshaw L B. A model for thrombin protection against endotoxin.  Thromb Res . 1984;  36 177-185
  CrossrefPubMedGoogle Scholar
• 102 Comp P C, Jacocks R M, Ferrell G L, Esmon C T. Activation of protein C in vivo.  J Clin Invest . 1982;  70 127-134
  PubMedGoogle Scholar
• 103 Cunningham M A, Romas P, Hutchinson P, Holdsworth S R, Tipping P G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages.  Blood . 1999;  94 3413-3420
  PubMedGoogle Scholar
• 104 Randolph G J, Luther T, Albrecht S, Magdolen V, Muller W A. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro.  Blood . 1998;  92 4167-4177
  PubMedGoogle Scholar